Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

G1 Therapeutics logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

Key Stats

Today's Range
$7.15
$7.15
50-Day Range
$7.08
$7.15
52-Week Range
$1.08
$7.19
Volume
N/A
Average Volume
1.70 million shs
Market Capitalization
$373.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

G1 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

GTHX MarketRank™: 

G1 Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 948th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for G1 Therapeutics.

  • Earnings Growth

    Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of G1 Therapeutics is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of G1 Therapeutics is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    G1 Therapeutics has a P/B Ratio of 10.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for GTHX.
  • Dividend Yield

    G1 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    G1 Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GTHX.
  • Search Interest

    1 people have searched for GTHX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, G1 Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.11% of the stock of G1 Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 24.21% of the stock of G1 Therapeutics is held by institutions.

  • Read more about G1 Therapeutics' insider trading history.
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GTHX Stock News Headlines

Drug developer seeks $100M for new cancer treatment
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
G1 Therapeutics Inc.
Hold Rating Affirmed Amid G1 Therapeutics’ Acquisition by Pharmacosmos
See More Headlines

GTHX Stock Analysis - Frequently Asked Questions

G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its earnings results on Wednesday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm earned $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative net margin of 76.93% and a negative trailing twelve-month return on equity of 136.98%.
Read the conference call transcript
.

G1 Therapeutics (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), NVIDIA (NVDA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/01/2024
Today
10/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTHX
CIK
1560241
Employees
170
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($0.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.97 million
Net Margins
-76.93%
Pretax Margin
-73.83%
Return on Equity
-136.98%
Return on Assets
-39.33%

Debt

Debt-to-Equity Ratio
1.34
Current Ratio
2.48
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$58.20 million
Price / Sales
6.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.68 per share
Price / Book
10.51

Miscellaneous

Outstanding Shares
52,281,000
Free Float
49,087,000
Market Cap
$373.81 million
Optionable
Optionable
Beta
1.66

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:GTHX) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners